Post-traumatic stress disorder

Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies

Retrieved on: 
Thursday, January 6, 2022

Prior to the amendments, restricted drugs such as psilocybin and MDMA were not accessible through SAP.

Key Points: 
  • Prior to the amendments, restricted drugs such as psilocybin and MDMA were not accessible through SAP.
  • Since the opening of our first Field Trip Health Center in Toronto in 2020, weve helped people around the world experience relief from suffering and find joy, wonder and fulfilment through our psychedelic therapies, said Hannan Fleiman, President of Field Trip.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.
  • Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022

Retrieved on: 
Thursday, January 6, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today provided a corporate update and highlighted development milestones anticipated in 2022.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today provided a corporate update and highlighted development milestones anticipated in 2022.
  • The company anticipates reporting results from the study in early to mid second quarter 2022.
  • The companys Phase 2b study of NYX-2925 in 300 patients with fibromyalgia is on track to report results in mid 2022.
  • In December 2021, Aptinyx initiated a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with PTSD.

Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States

Retrieved on: 
Wednesday, January 5, 2022

The total gross proceeds from the Offering (including the previously issued 1,622,000 ADSs) increased to approximately US$23 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bionomics.

Key Points: 
  • The total gross proceeds from the Offering (including the previously issued 1,622,000 ADSs) increased to approximately US$23 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bionomics.
  • The ADSs began trading on the Nasdaq Global Market on December 16, 2021, under the ticker symbol "BNOX".
  • Evercore ISI and William Blair acted as lead book-running managers for the Offering.
  • Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

Bob Woodruff Foundation Grant to Easter Seals Greater Houston Makes Healing and Growth Possible

Retrieved on: 
Wednesday, January 5, 2022

HOUSTON, Jan. 5, 2022 /PRNewswire/ -- Easter Seals Greater Houston (ESGH) is proud to have been selected for a grant from The Bob Woodruff Foundation to address urgent needs for veterans, caregivers, and military families.

Key Points: 
  • HOUSTON, Jan. 5, 2022 /PRNewswire/ -- Easter Seals Greater Houston (ESGH) is proud to have been selected for a grant from The Bob Woodruff Foundation to address urgent needs for veterans, caregivers, and military families.
  • Veteran, Service Member, and Military-Connected Family Program is the nonprofit's quickest growing sector as Houston has the 2nd highest Veteran population in the country.
  • With support from the Bob Woodruff Foundation, ESGH will continue supporting veterans like Chet Falkenhainer, a Navy Veteran that served from 1988-1997.
  • He earned 3 combat action ribbons along with 2 Navy Commendation Medals with "Combat V" device for valor on each.

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

Retrieved on: 
Tuesday, January 4, 2022

BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests.

Key Points: 
  • BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests.
  • Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
  • The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.

Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, January 4, 2022

Management will also be hosting virtual one-on-one meetings on Monday, January 10th and Tuesday, January 11th.

Key Points: 
  • Management will also be hosting virtual one-on-one meetings on Monday, January 10th and Tuesday, January 11th.
  • Event: Virpax Pharma Presentation at the H.C. Wainwright BioConnect Virtual Conference
    Time: On Demand from 7:00 a.m.
  • ET daily
    For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to [email protected] or call (212) 661-2231.
  • Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery.

PharmaTher Announces Publication of Research Data for KETABET™

Retrieved on: 
Tuesday, January 4, 2022

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a life sciences company focused on the development and commercialization of specialty ketamine prescription-based products, today announced the publication of a scientific article demonstrating the potential of KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain. The article titled, "Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice", is published in Biomedicine & Pharmacotherapy and can be found here.

Key Points: 
  • Based on the outcome from the ongoing observational studies, the Company will advance the KETABET program with its microneedle patch technology in Phase 2 clinical studies in H2-2022.
  • The present published study aimed to assess whether repeated co-treatment with betaine and ketamine improved behavioral impairments and hippocampal synaptic plasticity.
  • As such, we remain focused on expanding our clinical programs with KETABET for FDA approval.
  • PharmaTher has an exclusive license agreement with the National Health Research Institutes to develop and commercialize of the intellectual portfolio protecting KETABET, the patent titled "Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine".

Virtual Reality in Medical Market Size to Reach USD 3,309.9 Million in 2028 | Increasing Use of VR in Medical Marketing and Rising Prevalence of Diseases are Among Some Key Factors Driving Industry Growth, according to Emergen Research

Retrieved on: 
Monday, January 3, 2022

VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.

Key Points: 
  • VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.
  • Medical professionals can receive other beneficial training through VR, including learning about infectious disease control and human anatomy.
  • Technical limitations in various healthcare facilities associated with implementation of VR could hamper market revenue growth to some extent over the forecast period.
  • The global Virtual Reality (VR) in medical market size is expected to reach USD 3,975.0 Million in 2028 and register a revenue CAGR of 31.1% over forecast period.

Virtual Reality in Medical Market Size to Reach USD 3,309.9 Million in 2028 | Increasing Use of VR in Medical Marketing and Rising Prevalence of Diseases are Among Some Key Factors Driving Industry Growth, according to Emergen Research

Retrieved on: 
Monday, January 3, 2022

VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.

Key Points: 
  • VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.
  • Medical professionals can receive other beneficial training through VR, including learning about infectious disease control and human anatomy.
  • Technical limitations in various healthcare facilities associated with implementation of VR could hamper market revenue growth to some extent over the forecast period.
  • The global Virtual Reality (VR) in medical market size is expected to reach USD 3,975.0 Million in 2028 and register a revenue CAGR of 31.1% over forecast period.

Panaxia's facility in Malta granted EU-GMP Standard

Retrieved on: 
Monday, January 3, 2022

Dr. Dadi Segal, CEO of Panaxia:"The EU-GMP Standard granted to our facility in Malta is a significant regulatory achievement and a result of an in-depth and lengthy audit process by the European Health Authority.

Key Points: 
  • Dr. Dadi Segal, CEO of Panaxia:"The EU-GMP Standard granted to our facility in Malta is a significant regulatory achievement and a result of an in-depth and lengthy audit process by the European Health Authority.
  • Thus, the company became the first and only medical cannabis company in Israel to have a facility located in the territory of the European Union with an EU-GMP standard from a European authority.
  • Panaxia regularly manufactures and exports its products to these countries from its facility in Israel, the only one with EU-GMP standard in the country.
  • The EU-GMP standard for a production facility in Malta was adopted shortly after obtaining a marketing permit for cannabis extracts for vaporization in Germany.